Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2004-09-08
2008-10-14
Yu, Misook (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C530S388100
Reexamination Certificate
active
07435416
ABSTRACT:
The invention provides antibodies targeted at a tumor antigen prevalent on prostate tumors and methods useful in alleviating cancers expressing the antigen, as well as nucleic acids and cells for expressing the antibodies.
REFERENCES:
patent: 5208020 (1993-05-01), Chari et al.
patent: 5416064 (1995-05-01), Chari et al.
patent: 5648237 (1997-07-01), Carter
patent: 5789199 (1998-08-01), Joly et al.
patent: 5840523 (1998-11-01), Simmons et al.
patent: 5856136 (1999-01-01), Au-Young
patent: 6756036 (2004-06-01), Reiter et al.
patent: 2351887 (2000-06-01), None
patent: 2378946 (2001-01-01), None
patent: 425235 (1996-09-01), None
patent: WO 98/00540 (1998-01-01), None
patent: WO 98/40403 (1998-09-01), None
patent: WO 98/51805 (1998-11-01), None
patent: WO 98/51824 (1998-11-01), None
patent: WO 99/14328 (1999-03-01), None
patent: WO 00/32752 (2000-06-01), None
patent: WO 01/05427 (2001-01-01), None
Little et al., “Of Mice and Men: Hybridoma and Recombinant Antibodies.”Immunology Today21(8):364-370 (Aug. 2000).
Amara et al., “Monoclonal antibodies against prostate stem cell antigen inhibit prostate cancer tumour formation in SCID mice”Eur. Urol.(Abstract No. 420) 37(suppl 2):105 (2000).
Bahrenberg et al., “Reduced Expression of PSCA, a Member of the LY-6 Family of Cell Surface Antigens, in Bladder, Esophagus, and Stomach Tumors”Biochemical and Biophysical Research Communications275:783-788 (2000).
Dannull et al., “Prostate Stem Cell Antigen Is a Promising Candidate for Immunotherapy of Advanced Prostate Cancer”Cancer Research60:5222-5528 (2000).
Gingrich et al., “Pathologic Progression of Autochthonous Prostate Cancer in the TRAMP Model.”Prostate Cancer and Prostatic Diseases. 2:70-75 (1999).
Greenberg et al., “Prostate Cancer in a Transgenic Mouse.”Proc. Natl. Acad. Sci. USA92:3439-3443 (1995).
Gu et al., “Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer”Oncogene19:1288-1296 (2000).
Liu et al., “Eradication of Large Colon Tumor Xenografts by Targeted Delivery of Maytansinoids.”Proc. Natl. Acad. Sci. USA93:8618-8623 (Aug. 1996).
Reiter et al., “Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer”Proc. Natl. Acad. Sci. USA95(4):1735-1740 (Feb. 17, 1998).
Saffran et al., “Anti-PSCA mABs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts”Proc. Natl. Acad. Sci. USA98(5):2658-2663 (2001).
Devaux Brigitte
Keller Gilbert-Andre
Koeppen Hartmut
Lasky Lawrence A.
Genetech, Inc.
Tan Lee K.
Yu Misook
LandOfFree
Anti-tumor antibody compositions and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-tumor antibody compositions and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-tumor antibody compositions and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4016890